173 related articles for article (PubMed ID: 15722648)
1. Effect of cevimeline on salivary components in patients with Sjögren syndrome.
Suzuki K; Matsumoto M; Nakashima M; Takada K; Nakanishi T; Okada M; Ohsuzu F
Pharmacology; 2005 May; 74(2):100-5. PubMed ID: 15722648
[TBL] [Abstract][Full Text] [Related]
2. Sjögren's syndrome patients presenting with hypergammaglobulinemia are relatively unresponsive to cevimeline treatment.
Komai K; Shiozawa K; Tanaka Y; Yoshihara R; Tanaka C; Sakai H; Yamane T; Murata M; Tsumiyama K; Hashiramoto A; Shiozawa S
Mod Rheumatol; 2009; 19(4):416-9. PubMed ID: 19452244
[TBL] [Abstract][Full Text] [Related]
3. A double-blind, randomized, placebo-controlled study of cevimeline in Sjögren's syndrome patients with xerostomia and keratoconjunctivitis sicca.
Petrone D; Condemi JJ; Fife R; Gluck O; Cohen S; Dalgin P
Arthritis Rheum; 2002 Mar; 46(3):748-54. PubMed ID: 11920411
[TBL] [Abstract][Full Text] [Related]
4. Efficacy prediction of cevimeline in patients with Sjögren's syndrome.
Yamada H; Nakagawa Y; Wakamatsu E; Sumida T; Yamachika S; Nomura Y; Mishima K; Saito I
Clin Rheumatol; 2007 Aug; 26(8):1320-7. PubMed ID: 17221146
[TBL] [Abstract][Full Text] [Related]
5. The efficacy of cevimeline hydrochloride in the treatment of xerostomia in Sjögren's syndrome in southern Chinese patients: a randomised double-blind, placebo-controlled crossover study.
Leung KC; McMillan AS; Wong MC; Leung WK; Mok MY; Lau CS
Clin Rheumatol; 2008 Apr; 27(4):429-36. PubMed ID: 17899308
[TBL] [Abstract][Full Text] [Related]
6. Cevimeline for the treatment of xerostomia in patients with Sjögren syndrome: a randomized trial.
Fife RS; Chase WF; Dore RK; Wiesenhutter CW; Lockhart PB; Tindall E; Suen JY
Arch Intern Med; 2002 Jun; 162(11):1293-300. PubMed ID: 12038948
[TBL] [Abstract][Full Text] [Related]
7. [Clinical significance of cevimeline hydrochloride in the treatment of dry mouth in patients with Sjögren's syndrome].
Ogawa N; Shimoyama K; Karasawa H; Fukushima T; Masaki Y; Wano Y; Hirose Y; Sugai S
Nihon Rinsho Meneki Gakkai Kaishi; 2004 Oct; 27(5):330-7. PubMed ID: 15559322
[TBL] [Abstract][Full Text] [Related]
8. Salivary hypofunction and xerostomia: diagnosis and treatment.
Atkinson JC; Grisius M; Massey W
Dent Clin North Am; 2005 Apr; 49(2):309-26. PubMed ID: 15755407
[TBL] [Abstract][Full Text] [Related]
9. A new medication for treatment of dry mouth in Sjögren's syndrome.
al-Hashimi I; Taylor SE
Tex Dent J; 2001 Apr; 118(3):262-6. PubMed ID: 11404944
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic effect of cevimeline on dry eye in patients with Sjögren's syndrome: a randomized, double-blind clinical study.
Ono M; Takamura E; Shinozaki K; Tsumura T; Hamano T; Yagi Y; Tsubota K
Am J Ophthalmol; 2004 Jul; 138(1):6-17. PubMed ID: 15234277
[TBL] [Abstract][Full Text] [Related]
11. Cevimeline for the treatment of postirradiation xerostomia in patients with head and neck cancer.
Chambers MS; Posner M; Jones CU; Biel MA; Hodge KM; Vitti R; Armstrong I; Yen C; Weber RS
Int J Radiat Oncol Biol Phys; 2007 Jul; 68(4):1102-9. PubMed ID: 17379432
[TBL] [Abstract][Full Text] [Related]
12. Minor gland saliva flow rate and proteins in subjects with hyposalivation due to Sjogren's syndrome and radiation therapy.
Eliasson L; Almståhl A; Lingström P; Wikström M; Carlén A
Arch Oral Biol; 2005 Mar; 50(3):293-9. PubMed ID: 15740707
[TBL] [Abstract][Full Text] [Related]
13. Use of muscarinic agonists in the treatment of Sjögren's syndrome.
Fox RI; Konttinen Y; Fisher A
Clin Immunol; 2001 Dec; 101(3):249-63. PubMed ID: 11726216
[TBL] [Abstract][Full Text] [Related]
14. An immunohistochemistry-based study on aquaporin (AQP)-1, 3, 4, 5 and 8 in the parotid glands, submandibular glands and sublingual glands of Sjögren's syndrome mouse models chronically administered cevimeline.
Nakamura M; Saga T; Watanabe K; Takahashi N; Tabira Y; Kusukawa J; Yamaki K
Kurume Med J; 2013; 60(1):7-19. PubMed ID: 23925155
[TBL] [Abstract][Full Text] [Related]
15. Effects of pilocarpine hydrochloride and cevimeline on submandibular/sublingual salivation in rat xerostomia model produced by X-ray irradiation.
Omori Y; Asari T; Maruyama K; Kusama H; Kojima M; Shibata N
Arzneimittelforschung; 2003; 53(5):342-50. PubMed ID: 12854361
[TBL] [Abstract][Full Text] [Related]
16. Artificial saliva products and drugs to treat xerostomia.
Wynn RL; Meiller TF
Gen Dent; 2000; 48(6):630-6. PubMed ID: 12004654
[No Abstract] [Full Text] [Related]
17. Effect of Pilocarpine on impaired salivary secretion in patients with Sjögren's syndrome.
Jorkjend L; Bergenholtz A; Johansson AK; Johansson A
Swed Dent J; 2008; 32(2):49-56. PubMed ID: 18700333
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the discontinuation rates and side-effect profiles of pilocarpine and cevimeline for xerostomia in primary Sjögren's syndrome.
Noaiseh G; Baker JF; Vivino FB
Clin Exp Rheumatol; 2014; 32(4):575-7. PubMed ID: 25065774
[TBL] [Abstract][Full Text] [Related]
19. General pharmacological profile of the novel muscarinic receptor agonist SNI-2011, a drug for xerostomia in Sjögren's syndrome. 4th communication: Effects on gastrointestinal, urinary and reproductive systems and other effects.
Arisawa H; Fukui K; Imai E; Fujise N; Masunaga H
Arzneimittelforschung; 2002; 52(4):225-32. PubMed ID: 12040964
[TBL] [Abstract][Full Text] [Related]
20. Pilocarpine treatment in a mixed cohort of xerostomic patients.
Aframian DJ; Helcer M; Livni D; Robinson SD; Markitziu A; Nadler C
Oral Dis; 2007 Jan; 13(1):88-92. PubMed ID: 17241436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
